IBIO vs. DERM, CMRX, ASMB, YS, SLS, ANIX, MIST, ONCY, MRNS, and HOOK
Should you be buying iBio stock or one of its competitors? The main competitors of iBio include Journey Medical (DERM), Chimerix (CMRX), Assembly Biosciences (ASMB), YS Biopharma (YS), SELLAS Life Sciences Group (SLS), Anixa Biosciences (ANIX), Milestone Pharmaceuticals (MIST), Oncolytics Biotech (ONCY), Marinus Pharmaceuticals (MRNS), and Hookipa Pharma (HOOK). These companies are all part of the "pharmaceutical preparations" industry.
Journey Medical (NASDAQ:DERM) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.
In the previous week, iBio had 5 more articles in the media than Journey Medical. MarketBeat recorded 7 mentions for iBio and 2 mentions for Journey Medical. Journey Medical's average media sentiment score of 0.72 beat iBio's score of 0.32 indicating that iBio is being referred to more favorably in the news media.
iBio received 1 more outperform votes than Journey Medical when rated by MarketBeat users. However, 100.00% of users gave Journey Medical an outperform vote while only 33.33% of users gave iBio an outperform vote.
Journey Medical has higher revenue and earnings than iBio.
Journey Medical has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, iBio has a beta of -3.32, meaning that its stock price is 432% less volatile than the S&P 500.
iBio has a net margin of 0.00% compared to iBio's net margin of -5.20%. iBio's return on equity of -32.83% beat Journey Medical's return on equity.
Journey Medical presently has a consensus price target of $8.50, suggesting a potential upside of 96.76%. iBio has a consensus price target of $5.00, suggesting a potential upside of 98.41%. Given Journey Medical's higher possible upside, analysts plainly believe iBio is more favorable than Journey Medical.
7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 19.4% of Journey Medical shares are owned by insiders. Comparatively, 1.1% of iBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Journey Medical and iBio tied by winning 7 of the 14 factors compared between the two stocks.
Get iBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
